Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02649478 · ClinicalTrials.gov registry record · NA
Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate
A NA study, sponsored by Roxane Laboratories.
- Completed
- Registry status
- NA
- Development phase
- 1,430
- Enrollment target
NCT02649478: Completed NA study, sponsored by Roxane Laboratories.
NCT02649478 is a NA study that has completed, run by Roxane Laboratories. The registered enrollment target is 1,430 participants, roughly in line with the 1,404-participant average among 58,714 other NA trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02649478, a NA study, has completed, sponsored by Roxane Laboratories.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,430 participants
- Enrollment target
Study Summary
A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder Compared with Advair Diskus® 100/50 in Subjects with Asthma
Interventions
- DRUG Placebo
- DRUG Fluticasone / Salmeterol
- DRUG Advair Diskus 100/50
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,430 participants |
| Start Date | 2014-08 |
| Est. Completion | 2015-11 |
| Phase | NA |
What the finished NCT02649478 record still lists
NCT02649478 is an interventional study that assigns participants to a tested intervention. Its 1,430 participants enrollment target places it among the larger protocols in the corpus, roughly in line with the 1,404-participant average among 58,714 other NA trials with a reported enrollment target.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02649478 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02649478 about?
NCT02649478 is a clinical study titled "Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate". A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder Compared with Advair Diskus® 100/50 in Subjects with Asthma
What is the current status of trial NCT02649478?
This trial is currently completed. It is a NA study. The enrollment target is 1,430 participants. The study started on 2014-08. Estimated completion is 2015-11.
What interventions are being tested in trial NCT02649478?
The interventions under investigation include: Placebo (DRUG), Fluticasone / Salmeterol (DRUG), Advair Diskus 100/50 (DRUG).
Who is sponsoring clinical trial NCT02649478?
This trial is sponsored by Roxane Laboratories, which has 93 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02649478's enrollment target sits among peer trials
1,430 70th of 2000 higher than 1,931 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04754022 · 1,440 participants · NA
Transfusion Requirements in Younger Patients Undergoing Cardiac Surgery
- NCT04989790 · 1,440 participants · NA
Clinical Effectiveness of the "PICU Up!" Multifaceted Early Mobility Intervention for Critically Ill Children
- NCT06122246 · 1,440 participants · NA
PRESSURE CHECK: Find Your Path to Better Health
- NCT06324318 · 1,440 participants · Phase 2
Parenting in 2 Worlds Multisite Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia